tiprankstipranks
Orasure Technologies (CH:EP3)
:EP3

Orasure Technologies (EP3) Price & Analysis

0 Followers

EP3 Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Strong Liquidity And Zero DebtA $161 million cash balance and zero debt provide substantial financial flexibility for product launches, regulatory work, and operating investments. This low-leverage position reduces financing pressure while management works toward cash-flow breakeven and supports resilience through business volatility.
Sequential Revenue Recovery And Reiterated Growth OutlookSequential growth across the business, including stronger Diagnostics and SMS results, suggests demand is recovering from the recent trough. Reiterated full-year growth guidance provides a constructive operating direction and could improve scale, utilization, and earnings quality over coming quarters.
Regulatory Clearances Expand Diagnostic OpportunitiesFDA clearance for Colli-Pee Dx integrates OraSure’s collection technology with Roche’s major laboratory platforms and supports at-home STI sampling. Ebola 2.0’s EUA adds another deployable infectious-disease product, broadening the commercial pipeline and potential public-health reach.
Bears Say
Severe Revenue And Profitability DeteriorationThe sharp TTM revenue contraction and deeply negative operating and net margins indicate that the current expense base is not aligned with demand. Although gross margin remains near 42%, sustained operating losses could weaken reinvestment capacity and delay a durable return to profitability.
Meaningful Operating And Free-cash-flow BurnLarge negative operating and free cash flow show that the business is consuming liquidity despite its strong cash balance. The reversal from substantially positive 2023 cash generation highlights execution and working-capital volatility, making sustained improvement essential before growth investments become self-funded.
IntelliQ CT/NG Regulatory DelayThe IntelliQ setback removes a potentially important near-term product launch and leaves the timing of U.S. commercialization uncertain. Delayed regulatory progress can extend development spending, postpone revenue diversification, and increase reliance on existing products while the company addresses FDA requirements.

Orasure Technologies News

EP3 FAQ

What was Orasure Technologies’s price range in the past 12 months?
Currently, no data Available
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is CHF194.23M.
    When is Orasure Technologies’s upcoming earnings report date?
    Orasure Technologies’s upcoming earnings report date is Nov 10, 2026 which is in 61 days.
      How were Orasure Technologies’s earnings last quarter?
      Orasure Technologies released its earnings results on Aug 05, 2026. The company reported CHF0.073 earnings per share for the quarter, beating the consensus estimate of -CHF0.218 by CHF0.291.
        Is Orasure Technologies overvalued?
        According to Wall Street analysts Orasure Technologies’s price is currently same. Get more investment ideas with TipRanks Premium
          Does Orasure Technologies pay dividends?
          Orasure Technologies does not currently pay dividends.
          What is Orasure Technologies’s EPS estimate?
          Orasure Technologies’s EPS estimate is -0.19.
            How many shares outstanding does Orasure Technologies have?
            Orasure Technologies has 68,968,630 shares outstanding.
              What happened to Orasure Technologies’s price movement after its last earnings report?
              Orasure Technologies reported an EPS of CHF0.073 in its last earnings report, beating expectations of -CHF0.218. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of Orasure Technologies?
                Currently, no hedge funds are holding shares in CH:EP3
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Orasure Technologies Stock Smart Score

                  Company Description

                  Orasure Technologies

                  OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

                  Orasure Technologies (EP3) Earnings & Revenues

                  EP3 Earnings Call

                  Q2 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.View all CH:EP3 earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  InfuSystem Holdings
                  Stereotaxis
                  Utah Medical Products
                  Microbot Medical
                  Sanara MedTech
                  Popular Stocks